Moxonidin 1 A Pharma (Moxonidine)

Moxonidine, the active ingredient in Moxonidin 1 A Pharma, is an imidazoline receptor agonist presented as an oral tablet for oral use. It is used to lower blood pressure in patients with essential hypertension.

GNH USA supplies Moxonidin 1 A Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine is an antihypertensive agent that acts on central imidazoline I1 receptors to control elevated blood pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: helps achieve target systolic pressure when isolated elevation is present. - Hypertension in patients intolerant to other agents: provides an alternative mechanism of action for blood‑pressure control.

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: sensation of reduced salivation. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headed feeling, especially on standing. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or urge to vomit. - Peripheral edema: mild swelling of the lower limbs.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: abnormally low heart rate. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or swelling of face and throat. - Syncope: sudden loss of consciousness. - Renal impairment: worsening kidney function in susceptible individuals.

Before initiating therapy, clinicians should assess patient history and monitor for potential risks.

- Cardiovascular disease: evaluate for existing heart conditions before use. - Renal impairment: adjust monitoring in patients with reduced kidney function. - Hepatic disease: consider liver function tests prior to treatment. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Concomitant antihypertensives: monitor for additive blood‑pressure lowering effects. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Moxonidine may interact with other medicines that influence blood pressure or sympathetic activity.

Major Interactions (Avoid): - Combined use with other central antihypertensives (e.g., clonidine) may cause excessive hypotension. - Potent CYP2D6 inhibitors: may increase plasma concentrations of moxonidine.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance orthostatic hypotension; monitor electrolytes. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect. - Beta‑blockers: additive heart‑rate lowering; observe for bradycardia.